Research programme: microRNA therapeutics - AstraZeneca/Regulus TherapeuticsAlternative Names: anti-microRNA-103/107; anti-microRNA-19; anti-microRNA-33a; anti-microRNA-33b; anti-miR-103/107; anti-miR-19; anti-miR-33a; anti-miR-33b; microRNA-103/107 therapeutics; microRNA-19 therapeutics; microRNA-33 therapeutics
Latest Information Update: 26 Sep 2014
At a glance
- Originator AstraZeneca; Regulus Therapeutics
- Class Antisense oligonucleotides; MicroRNAs
- Mechanism of Action MicroRNA inhibitors; MicroRNA modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Atherosclerosis; Cancer; Cardiovascular disorders; Metabolic disorders